gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CTXRHealthcarePharmaceuticals

Citius Pharmaceuticals Inc. Common (CTXR)

$0.5510−3.87%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$0.55▼ 63.82% in range
Nov 3, 2025Low $0.37 · High $1.52Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Citius Pharmaceuticals Inc. Common closed at $0.55 on Nov 4, down 3.87%, 63.8% below its 52-week closing high. Volume of 138.1K shares was 0.51× its 20-day average (below normal).

Split-adjusted performance: +14.6% over one month, -17.3% over six months, -63.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.49M, with a net margin of -593.3%.

Short interest was 5.7M shares at the Oct 15 settlement, up 2.0% from the prior report (21.9% of float, 30.3 days to cover).

Market cap$15.1M27.5M shares
Revenue · quarter$1.5M—
Diluted EPS$-0.34—
P/E · TTM—P/S 2.1×
Net margin-593.3%Gross 67.1%
Dividend yieldNone
52-week range0.37 – 1.52−63.8% from high
Volume138.1K0.51× 20-day avg
Volatility · 60d96.0%Annualised
Short % of float21.9%30.3 days to cover
Net cash$10.6MCash $17.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.8%1M +14.6%3M −14.2%6M −17.3%YTD −29.1%1Y −63.8%3Y −97.1%5Y −98.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum59
Revenue growth—
Net margin28
Value (low P/E)—
Size19

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.7M+2.0% vs prior
Days to cover30.3Settled Oct 15
% of float21.9%
Short vol. 10d57.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CTXRCitius Pharmaceuticals$0.5510−3.87%−17.3%—−593.3%—$15.1M
BOLTBolt Biotherapeutics$6.54−0.46%+42.5%−99.7%−154400.0%—$15.4MCompare
KYNBKyntra Bio$3.96−8.12%−44.4%———$16.0MCompare
NEUPNeuphoria Therapeutics$2.98−0.33%−44.6%———$16.1MCompare
MTEXMannatech$8.64−0.06%+77.0%+3.8%3.8%—$16.7MCompare
MRKRMarker Therapeutics$1.01+2.76%−30.8%———$16.8MCompare
BFRIBiofrontera$0.9038+1.56%−20.7%+32.9%−5.0%—$13.4MCompare
ALLRAllarity Therapeutics$1.08−4.42%−27.0%———$17.2MCompare
DAREDare Bioscience$0.6619+1.83%−79.1%—−1590.4%—$13.0MCompare

News about Citius Pharmaceuticals

All news →
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Benzinga · Feb 13, 2026▲ PositiveCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Benzinga · Feb 13, 2026▲ Positive

Quick answers

What does Citius Pharmaceuticals Inc. Common do?
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities.
What is CTXR's market cap?
$15.13M, based on the Nov 4 close of $0.55.
Does Citius Pharmaceuticals Inc. Common pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CTXR is sold short?
5.7M shares, 21.9% of float, as of Oct 15, 2026.
What sector is CTXR in?
Healthcare, in the Pharmaceuticals industry.

About Citius Pharmaceuticals

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

HQ: Cranford, NJ23 employeesListed Oct 18, 2011citiuspharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology